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Abstract 
Medical therapy for Cushing’s disease (CD) is currently based on agents mainly targeting adrenocortical function. Lately, pituitary-directed 
drugs have been developed, with limited efficacy. Mitotane, a potent adrenolytic drug, has been recently investigated for the treatment of 
CD, but the direct pituitary effects have not been clarified so far. The aim of our study was to investigate whether mitotane may affect 
corticotroph function and cell survival in the mouse pituitary cell line AtT20/D16v-F2 and in the primary cultures of human ACTHsecreting 
pituitary adenomas, as an in vitro model of pituitary corticotrophs. We found that in the AtT20/D16v-F2 cell line and in primary cultures, 
mitotane reduces cell viability by inducing caspase-mediated apoptosis and reduces ACTH secretion. In the AtT20/D16v-F2 cell 
line, mitotane reduces Pomc expression and blocks the stimulatory effects of corticotropin releasing hormone on cell viability, ACTH 
secretion, and Pomc expression. These effects were apparent at mitotane doses greater than those usually necessary for reducing cortisol 
secretion in Cushing’s syndrome, but still in the therapeutic window for adrenocortical carcinoma treatment. In conclusion, our results 
demonstrate that mitotane affects cell viability and function of human and mouse ACTH-secreting pituitary adenoma cells. 
These data indicate that mitotane could have direct pituitary effects on corticotroph cells. 
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Introduction 
Cushing’s disease (CD), characterized by hypercortisolism due to excessive secretion of ACTH by the pituitary gland, is a rare 
disease with an incidence between 0.7 and 2.4 cases per million per year (Patil et al. 2008). Currently, the treatment of choice for 
patients with CD is surgery, but late recurrence occurs in 5–20% of patients (Atkinson et al. 2005). Although a variety of treatments 
are available, pituitary irradiation is a good option for aggressive CD that fails to respond to surgery, invades the cavernous sinus, or 
relapses following an initial remission, but the treatment is associated with important side effects (Mahmoud-Ahmed & Suh 2002). 
Laparoscopic bilateral adrenalectomy can be safely and effectively employed to treat CD but needs permanent glucocorticoid 
supplementation (Porpiglia et al. 2004). Several medical therapies, including steroidogenic inhibitors, centrally acting agents, and 
glucocorticoid receptor inhibitors, are currently being used or investigated as a potential treatment for CD (Biller et al. 2008, Feelders 
et al. 2010), but their efficacy was found to be unpredictable (Tritos & Biller 2012). Recently, a retrospective study has highlighted 
the efficacy of mitotane therapy in CD treatment (Baudry et al. 2012). Mitotane (o,p0-DDD), a derivative of the insecticide  
dichlorodiphenyltrichloroethane, has been widely used for treatment of advanced (unresectable, metastatic, or relapsed) 
adrenocortical carcinoma (ACC; Bergenstal et al. 1960, Young et al. 1973, Hogan et al. 1978, Lughezzani et al. 2010) and is 
increasingly used in adjuvant settings (Fassnacht et al. 2012). Mitotane concentrations are associated with both efficacy and 
toxicity (Haak et al. 1994, Terzolo et al. 2000) and blood levels R14 mg/l predict ACC tumor response (Haak et al. 1994, Hermsen et 
al. 2011). A concentration range between 14 and 20 mg/l (corresponding to 44–62 mM) is considered as the ACC therapeutic 
window (Terzolo et al. 2000, Lee 2007, Hermsen et al. 2011), while lower doses of mitotane have been demonstrated to control 
hypercortisolism in the settings of CD (Baudry et al. 2012). The latter effect is usually ascribed to the adrenolytic action of 
mitotane, but a central inhibitory action on corticotrophs has never been investigated. We previously demonstrated that mitotane 
reduces both secretory activity and cell viability of pituitary TSH-secreting mouse cells (Zatelli et al. 2010), suggesting a possible 
direct effect on pituitary cells. Therefore, the aim of our study was to investigate whether mitotane may affect corticotroph function 
and cell survival in vitro. 
  
 Materials and methods 
Reagents 
Mitotane (Supelco, Bellefonte, PA, USA) was resuspended 
in absolute ethanol. Therefore, control cells have been 
incubated in culture medium containing 0.1% ethanol in 
all experiments. All reagents were purchased from Sigma if 
not otherwise indicated. 
Cell culture 
The mouse ACTH-secreting pituitary adenoma cell line, 
AtT20/D16v-F2, was obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). The cell 
line was maintained in DMEM (Invitrogen) supplemented 
with 10% horse serum (HS) (LGC Standards, Milano, Italy) 
and antibiotic antimycotic (EuroClone, Milano, Italy) at 
37 8C in 5% CO2, as described previously (Gentilin et al. 
2013). Before each experiment, cells were incubated in 
0.5% HS medium for 48 h followed by a 24-h incubation in 
10% HS medium. 
The human thyroid follicular epithelial cell line, 
Nthy-ori 3-1 (ECACC, Salisbury, UK), was maintained in 
RPMI-1640 medium (Invitrogen) supplemented with 
10% fetal bovine serum (FBS) (LGC Standards) and 
antibiotic antimycotic (EuroClone) as described previously 
(Caselli et al. 2012). 
The human endometrial stromal cell line, T-HESC 
(ATCC),wasmaintained inDMEM/F12 (Invitrogen) supplemented 
with 1.5 g/l sodium bicarbonate, 1% ITSCPremix, 
500 ng/ml puromycin, and 10% charcoal/dextran-treated 
FBS (LGC Standards). 
The human kidney cell line, 4/5 (generously provided 
by Dr Gianluca Aguiari, Department of Biomedical and 
Specialty Surgical Sciences, University of Ferrara), was 
maintained in DMEM (Invitrogen) supplemented with 
10% FBS (LGC Standards) and antibiotic antimycotic 
(EuroClone). 
Tissue collection and primary culture 
The liver sample was derived from a patient diagnosed 
with liver hyperplasia and operated on at the University 
of Ferrara (Section of Endocrinology and Institute of 
Surgery). The pituitary adenoma samples derived from 
five patients were operated on for ACTH-secreting 
pituitary adenomas at the Department of Neurosurgery, 
Ospedale Maggiore – Bellaria, Bologna, Italy. Tissues were 
collected following the guidelines of the local committee 
on human research and immediately minced in RPMI- 
1640 medium (Invitrogen) under sterile conditions. 
Primary cultures were then prepared as described 
previously (Zatelli et al. 2006, Martı´nez-Fuentes et al. 
2011). Informed consent of the patients was obtained 
for disclosing clinical investigation and performing the 
in vitro study. 
Viable cell number assessment 
Variations in cell number were assessed by the ATPlite 
assay (PerkinElmer, Waltham, MA, USA), as described 
previously (Zatelli et al. 2007). Briefly, the cells were seeded 
at 9!103 cells/well in 96-well white plates and then 
exposed to test substances. After incubation time, substrate 
solution was added directly to the cell culture plates 
at room temperature. The plates were shaken at 700 r.p.m. 
for 2 min and then measured for luminescent output 
(relative light units (RLU)) by Victor3 1420 Multilabel 
Counter (PerkinElmer). Results are expressed as mean 
valueGS.E.M. percent cell viability vs vehicle-treated control 
cells in five independent experiments in six replicates. 
Caspase activity 
Caspase activity was measured using the Caspase-Glo 3/7 
assay (Promega) following the manufacturer’s instruction 
as described previously (Tagliati et al. 2010). Results are 
expressed as mean valueGS.E.M. percent RLU vs vehicletreated 
control cells in five independent experiments in 
six replicates. 
ACTH secretion 
ACTH secretion was evaluated by measuring mouse ACTH 
immunoreactivity in the conditioned culture medium 
with the ACTH ‘Ultra Sensitive’ lumELISA kit (Calbiotech, 
Spring Valley, CA, USA). Hormone assays were performed 
in duplicate after appropriate sample dilutions. The 
sensitivity was !1 pg/ml at the 95% confidence limit. 
Intra- and interassay CV were 6 and 8.7% respectively. 
The assay results were normalized by cell number, as 
determined from the ATPlite assay. Results are expressed 
as the mean valueGS.E.M. percent ACTH concentration vs 
vehicle control cells in seven experiments in duplicate. 
Pomc gene expression 
Total RNA from treated cells was extracted with TRIzol 
reagent (Invitrogen) and treated with RNase-free DNase 
(Promega), as previously reported (Minoia et al. 2012). The 
Experion automated electrophoresis system (Bio-Rad) was 
used to determine the concentration and integrity of RNA 
samples. Only samples with RNA quality index O9 were 
reverse transcribed using the first-strand cDNA synthesis 
kit (Invitrogen) following the manufacturer’s instructions. 
Pomc expression evaluation was performed by relative 
quantitative real-time PCR (QRT-PCR). All QRT-PCRs were 
conducted with the TaqMan gene expression assay 
(Applied Biosystems), run on Applied Biosystems 7700 
ABI Prism thermal cycler, and analyzed with the SDS 1.9 
Software (Applied Biosystems). Glyceraldehyde 3-phosphate 
dehydrogenase was identified as the most stable 
reference gene from a set of five tested candidate housekeeping 
genes (Table 1) by the geNorm software, version 
3.4 (Vandesompele et al. 2002). Relative expression ratio of 
Pomc mRNA (assay ID Mm00435874_m1; Applied Biosystems) 
was calculated by applying the method described by 
Pfaffl (2001). Results are expressed as mean valueGS.E.M. 
percent Pomc expression vs vehicle-treated control cells 
from at least five independent experiments in five 
replicates. 
Statistical analysis 
Results were expressed asGS.E.M. and analyzed statistically 
using Student’s t-tests to evaluate individual differences 
between means. Differences were considered significant 
at P!0.05. 
Results 
Effects of mitotane on basal and corticotropin-releasing 
hormone-induced AtT20/D16v-F2 cell viability 
In order to determine the effects of mitotane on corticotroph 
cell viability, the latter was assessed in AtT20/D16v- 
F2 after 6- and 24-h treatment without or with increasing 
mitotane concentrations (10–100 mM, corresponding to 
plasma levels of 3.2–32 mg/l). As shown in Fig. 1A, after 
6 h, mitotane significantly reduced cell viability at 100 mM 
(K29%; P!0.01); after 24 h, mitotane significantly 
Table 1 Primers and probe for candidate housekeeping genes 
Gene Primers and probe 
Cyclophilin Primer reverse 50-AAACAGCTCGAAGGAGACGC-30 
Primer forward 50-ACCGTGTTCTTCGACATCACG-30 
Probe 50-60FAM-ATGACGAGCCCTTGGG-MGB-30 
Ribosomal L37 Primer reverse 50-CAGCTGCCCTCTTGGGTTT-30 
Primer forward 50-CCGCAGATTCAGACATGGATT-30 
Probe 50-60FAM-TGAGGGAACAACGCC-MGB-30 
18S 4319413E TaqMan endogenous control; Applied Biosystems 
Gadph 4352339E TaqMan endogenous control; Applied Biosystems 
b-Actin 4352341E TaqMan endogenous control; Applied Biosystems 
reduced cell viability at concentrations R40 mM, from 8% 
(P!0.05) to 45% vs control (P!0.01). 
Time-course experiments showed that treatment with 
100 nM corticotropin-releasing hormone (CRH) significantly 
induced cell viability after incubation up to 6 h 
by w20% (P!0.05; data not shown). No effect was 
observed for longer incubation intervals. As the cells 
were incubated with CRH without any treatment renewal, 
we hypothesized that CRH will be degraded at long 
exposure time; therefore, experiments employing CRH 
were performed with a 6-h incubation time. 
To investigate whether mitotane may influence CRHinduced 
AtT20/D16v-F2 cell viability, the latter was 
measured after a 6-h incubation with CRH alone or in 
combination with increasing mitotane concentrations 
(10–100 mM). As shown in Fig. 1B, CRH induced a 
significant (P!0.05) increase in AtT20/D16v-F2 cell 
viability (C25%), which was significantly reduced by 
mitotane at all concentrations (from 12 to 50% when 
compared with CRH-treated cells). 
Effects of mitotane on human ACTH-secreting pituitary 
adenoma cell viability 
In order to determine the effects of mitotane on human 
ACTH-secreting pituitary adenoma cell viability, the latter 
was assessed in human primary cultures from ACTHsecreting 
pituitary adenomas after 24-h treatment without 
or with increasing mitotane concentrations (10–100 mM, 
corresponding to plasma levels of 3.2–32 mg/l). As shown 
in Fig. 1C, after 24 h, mitotane significantly reduced cell 
viability at concentrations R40 mM, from 15% (P!0.01) 
to 55% vs control (P!0.01). 
Effects of mitotane on cell viability of thyroid, 
endometrial, renal, and liver cells 
In order to determine the specificity ofmitotane effects, cell 
viabilitywas assessedinNTHY-ori 3-1, T-HESC,4/5cell lines, 
and in a liver primary culture after 24-h treatment without 
or with increasing mitotane concentrations (10–100 mM, 
corresponding to plasma levels of 3.2–32mg/l). As shown 
in Fig. 2,mitotane did not significantlymodify the viability 
of any investigated cell line. 
Effects of mitotane on AtT20/D16v-F2 apoptosis and 
CRH influence 
To investigate whether mitotane reduces cell viability by 
activating apoptosis, caspase 3/7 activity was measured in 
AtT20/D16v-F2 cells incubated for 6 and 24 h in 
the presence of increasing mitotane concentrations 
(10–100 mM). As shown in Fig. 3A, mitotane significantly 
induced apoptosis at 40–100 mMafter both 6 h (from 48 to 
434%; P!0.01) and 24 h (from C83 to C763%; P!0.01) 
when compared with vehicle-treated control cells. We 
observed that, after 6 h, at concentrations !100 mM 
mitotane significantly induced caspase activation but did 
not affect cell viability, suggesting that a short exposure 
time does not compromise the viability of corticotroph 
cells but commits them to apoptosis. 
To investigate the influence of CRH on mitotaneinduced 
apoptosis, caspase 3/7 activity was measured in 
AtT20/D16v-F2 cells incubated for 6 h with CRH alone or 
in combination with increasing mitotane concentrations. 
As shown in Fig. 3B, CRH did not significantly affect basal 
caspase 3/7 activity but completely blocked the proapoptotic 
effects of mitotane at 40 mM. However, the 
inhibitory effect of CRH on mitotane-induced caspase 
activation was lost partially at 60 mM and completely at 
100 mM mitotane. 
Effects of mitotane on human ACTH-secreting pituitary 
adenoma primary culture apoptosis 
To investigate whether mitotane reduces cell viability in 
human ACTH-secreting pituitary adenoma primary cultures 
by activating apoptosis, caspase 3/7 activity was 
measured after incubation for 24 h in the presence of 
increasing mitotane concentrations (10–100 mM). As 
shown in Fig. 3C, mitotane significantly induced apoptosis 
at 40–100 mM (from C60 to C620%; P!0.01) when 
compared with vehicle-treated control cells. 
Effects of mitotane on basal ACTH secretion 
To determine the effects of mitotane on ACTH secretion, 
ACTH levels were assessed in conditioned medium from 
AtT20/D16v-F2 cells treated for 6 and 24 h with increasing 
mitotane concentrations (10–100 mM). As shown in Fig. 4A, 
mitotane significantly reduced basal ACTH secretion after a 
6-h treatment at both 80 and 100 mM (K65 and K87% 
respectively; P!0.01). After 24 h, mitotane significantly 
reduced ACTH secretion at R60 mM (from 40 to 96%). 
ACTH levels were also assessed in conditioned 
medium from human ACTH-secreting pituitary adenoma 
primary cultures treated for 24 h with increasing mitotane 
concentrations (10–100 mM). As shown in Fig. 4B, mitotane 
significantly reduced basal ACTH secretion at 
R60 mM (from 35 to 94%; P!0.01). 
Effects of mitotane on CRH-stimulated ACTH secretion 
To evaluate ACTH secretory response to CRH in vitro, 
AtT20/D16v-F2 cells were incubated for 0, 2, 5, 10, 15, and 
30 min with CRH at 100 nM, a concentration at which 
CRH is known to induce ACTH secretion in these cells 
(Strowski et al. 2002). ACTH was then assayed in the 
condition medium. As shown in Fig. 5A, CRH significantly 
induced ACTH secretion up to 15 min, reaching the peak 
value after 2 min (C80%; P!0.01 vs time point 0). 
To determine whether mitotane affects CRH-induced 
ACTH secretion by AtT20/D16v-F2 cells, the cells were 
treated with 10–100 mM mitotane for 6 and 24 h. The 
medium was then removed and cells were stimulated with 
100 nM CRH or vehicle for 2 min; then, ACTH concentration 
was evaluated. As shown in Fig. 5B, basal and CRHinduced 
ACTH secretion was higher after 6 h when 
compared with 24-h vehicle incubation. Pre-incubation 
for 6 h with mitotane at R40 mM significantly reduced 
both basal and CRH-induced ACTH secretion, which was 
completely suppressed atR80 mMmitotane. Pre-incubation 
for 24 h with mitotane at R10 mM significantly reduced 
both basal and CRH-induced ACTH secretion, which was 
completely suppressed at R80 mM mitotane. 
To determine whether mitotane affects CRH-induced 
ACTH secretion by human ACTH-secreting pituitary 
adenoma primary cultures, the cells were treated with 
40–60 mM mitotane for 24 h and then stimulated with 
100 nM CRH or vehicle for 2 min; then, ACTH 
concentration was evaluated. As shown in Fig. 5C, CRH 
induced ACTH secretion by primary cultured cells (C40%; 
P!0.01); pre-incubation with mitotane at 40–60 mM 
significantly (P!0.01) reduced both basal and 
CRH-induced ACTH secretion. 
Effects of mitotane on Pomc mRNA expression and 
CRH influence 
To determine the effects of mitotane on Pomc mRNA 
expression, Pomc mRNA levels were assessed in AtT20/ 
D16v-F2 cells treated for 6 h with 10–100 mM mitotane. As 
shown in Fig. 6, mitotane significantly (P!0.01) reduced 
basal Pomc mRNA expression by w70% at all concentrations 
tested. On the contrary, 100 nM CRH significantly 
(P!0.01) induced Pomc mRNA expression (C100% 
vs vehicle control cells), an effect completely counteracted 
by mitotane at all concentrations tested. 
Discussion 
Our study provides for the first time evidence that 
mitotane has a direct and important action on human 
ACTH-secreting pituitary adenoma primary cultures and 
on the AtT20/D16v-F2 cell line, whose function may be 
greatly and quickly compromised. This inhibitory effect is, 
at least in part, due to direct inhibition of corticotroph cell 
viability, which is reduced by mitotane already after 6 h at 
high doses in AtT20/D16v-F2 cells and after 24 h at the 
concentrations corresponding to the ACC therapeutic 
window in both mouse and human corticotroph cells. 
These data indicate that exposure time may have a 
differential impact on corticotroph viability, in agreement 
with a previous report indicating that mitotane reduces 
cell viability of a TSH-secreting pituitary cell line in a 
similar fashion (Zatelli et al. 2010). In addition, the 
evidence that caspase activation precedes cell viability 
reduction after mitotane treatment, supports the 
hypothesis that mitotane rapidly commits corticotroph 
cells to apoptosis which, in turn, after a long exposure 
time, results in cell viability reduction. On the other hand, 
mitotane does not affect cell viability of the endocrine cell 
line NTHY-ori 3-1, indicating that mitotane cytotoxic 
effects are not generalized to endocrine cells. Moreover, 
the viability of non-endocrine cells, such as T-HESC and 
4/5 cell lines and liver primary culture, is not influenced 
by the drug, supporting the hypothesis that mitotane acts 
rapidly with a specific effect at the pituitary level. 
Previous clinical reports showed that in CD patients, 
mitotane, owing to its adrenolytic action, is highly 
effective in the long-term suppression of hypercortisolism 
(Luton et al. 1979, Schteingart et al. 1980), at concentrations 
lower that those employed for ACC treatment 
(Gross et al. 2007, Murao et al. 2010, Baudry et al. 2012), 
but central inhibitory actions have been overlooked. 
Recently, Baudry et al. (2012) reported that in 24.5% of 
CD patients treated with mitotane as first-line treatment 
and with initial negative magnetic resonance imaging, a 
pituitary adenoma became apparent during or at the end 
of the treatment. These results may be explained by the 
anti-cortisolic effects exerted by mitotane at the doses 
employed in this study, corresponding to w20–30 mM, 
which are approximately twofold lower than those 
employed in our experiments. Indeed, in their hands, 
mitotane significantly lowered cortisol levels in the 
majority of patients, with a consequent disappearance of 
negative feedback at the pituitary level. The latter allowed 
the increase in ACTH plasma levels and the visualization 
of a pituitary adenoma in 12 patients (Baudry et al. 2012), 
similar to what happens in Nelson’s syndrome. Of these 
patients, ten had been operated on, but the authors do not 
disclose pathological characteristics of the adenomas, 
such as ki-67 (Fusco et al. 2008), which may be helpful in 
understanding the direct effects of mitotane at pituitary 
level. By contrast, in our experimental settings, we 
observed a reduction in corticotroph function and cell 
viability at higher mitotane concentrations (R40 mM), 
suggesting that direct pituitary effects may become 
apparent only in the presence of drug concentrations in 
the ACC therapeutic window. This hypothesis is further 
strengthened by the evidence that, upon (low-dose) 
mitotane withdrawal, w70% of patients showed recurrence 
of hypercortisolism (Baudry et al. 2012), suggesting 
a lack of central effect when mitotane plasma level is 
!40 mM. Our data show that higher mitotane doses 
impair corticotroph function and viability and therefore 
might be effective in controlling the disease at the 
pituitary level and in preventing recurrence after withdrawal. 
Clinical studies are necessary to clarify this issue. 
The hypophysiotropic hormone CRH (Florio et al. 
2007) has been previously demonstrated to significantly 
stimulate AtT20/D16v cell proliferation (van Wijk et al. 
1995). Our results show that CRH induces cell viability 
only in the short term, suggesting a protective rather than 
a proliferative effect of this peptide on corticotroph cells. 
In keeping with our results, Lezoualc’h et al. (2000) 
indicated CRH as an endogenous protective neuropeptide 
against oxidative cell death in addition to its function in 
the HPA system. In addition, our data show that mitotane 
dose dependently reduced the stimulatory effects of 
CRH on mouse corticotroph cell viability. These data 
suggest that ACTH-secreting cells may become refractory 
to physiological stimuli, such as CRH, after exposure to 
mitotane. Moreover, we observed that the inhibitory 
effects of mitotane on human and mouse ACTH-secreting 
pituitary adenoma cell viability are, at least in part, due to 
apoptosis induction, as previously reported in other 
experimental models (Pushkarev et al. 2007, Zatelli et al. 
2010). In our settings, caspase activation is prompted 
quickly and persists for at least 24 h. We also observed 
that, after 6 h, at concentrations !100 mM, mitotane 
significantly induced caspase activation but did not affect 
cell viability, suggesting that a very short exposure time 
does not compromise the viability of corticotroph cells but 
commits them to apoptosis. 
As already noted, mitotane, at concentrations lower 
than those reached in vivo, is able to reduce steroids and 
TSH secretion in adrenocortical and pituitary TSHsecreting 
cell lines respectively (Stigliano et al. 2008, 
Zatelli et al. 2010). Our findings support the evidence 
that mitotane affects pituitary function, also reducing the 
secretory activity of corticotroph cells. Mitotane inhibits 
ACTH secretion at high concentrations (80–100 mM) after 
6 h of incubation in AtT20/D16v-F2 cells and at R60 mM 
after 24 h of exposure in human and mouse ACTHsecreting 
pituitary adenoma cells. This indicates, as 
previously suggested, that mitotane has a toxic effect on 
corticotroph function, providing further support to the 
use of this drug for persistent and refractory CD (Kawai 
Journal of Endocrinology et al. 1999, Baudry et al. 2012). A recent study reported that 
plasma mitotane concentrations O8.5 mg/l (corresponding 
to 24 mM) are sufficient to achieve CD control 
(Baudry et al. 2012). On the contrary, in our settings, 
mitotane reduced ACTH secretion at a concentration 
of 60 mM, suggesting that a greater exposure time may be 
needed to affect pituitary hormonal secretion. 
In patients treated with adjuvant mitotane following 
complete ACC removal, ACTH levels are often nonsignificantly 
increased as it should be expected by 
mitotane-induced inhibition of adrenal steroidogenesis 
(Daffara et al. 2008). Furthermore, both Takamatsu et al. 
(1981) and Kawai et al. (1999) suggested that mitotane 
had an effect on corticotrophs, reporting that mitotane 
maintenance therapy may be a good treatment option for 
persistent and intractable CD. These findings support the 
hypothesis that mitotane impairs ACTH secretion and has 
a direct action on corticotroph cells when employed at 
high concentrations (i.e. those used for ACC). 
Our results also show that AtT20/D16v-F2 cells 
respond to CRH stimulation with a rapid and significant 
increase in ACTH secretion. The stimulatory effect of CRH, 
however, is completely blunted by concentrations of 
mitotane R40 mM after 6 h of exposure and at lower 
concentrations after 24 h. These data indicate that 
mitotane rapidly affects the capability of adrenocorticotroph 
cells to respond to physiological stimuli, in keeping 
with the results obtained on cell viability. The antisecretory 
effects of mitotane on corticotroph cells are 
further supported by data from primary cultures, wherein 
CRH stimulatory effect is completely abolished by 
mitotane at the concentrations corresponding to the 
ACC therapeutic window. These results are in line with 
evidence that mitotane strongly inhibits TRH-induced 
TSH secretion, supporting the hypothesis that this drug 
acts rapidly and profoundly with a generalized effect at 
the pituitary level. This hypothesis is further strengthened 
by evidence that, after 6 h, mitotane reduces Pomc 
expression independently of the concentration and 
regardless of CRH stimulation. Indeed, in keeping with 
the report by Aoki et al. (1997), CRH significantly induces 
Pomc expression, but, in our hands, it is not capable of 
rescuing cell function from mitotane toxic effects. Our 
data indicate that the effects of mitotane on ACTH 
secretion are not completely dependent on the effects on 
Pomc expression. Incubation with mitotane reduces shortterm 
ACTH spontaneous release, suggesting that mitotane, 
besides affecting Pomc gene transcription, may 
impair ACTH release, also influencing secretory 
mechanisms. 
In conclusion, our results demonstrate that mitotane 
reduces cell viability and function of mouse and human 
pituitary ACTH-secreting adenoma cells, suggesting a 
direct pituitary effect of mitotane. In addition, we provide 
evidence for a higher sensitivity of corticotroph cells to 
mitotane, as other cell lines originating from tissues 
different from pituitary (and also of non-endocrine lineage) 
are not sensitive to the inhibitory effects of mitotane 
during short-time exposure. 
However, the promising in vitro data showing efficacy 
of mitotane in CD at the doses used for ACC within 24 h 
must be confirmed in vivo for a longer period of time in 
clinical trials, balancing the efficacy of ACTH secretion 
reduction with the development of side effects. 
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